1.44

7.10% -0.11

Pre-market: 1.45 0.01 +0.69%

Werewolf Therapeutics Inc (HOWL)

Overview News Price History Option Chain Financials Discussions Forecast

Werewolf Therapeutics Inc stock is traded at $1.44, with a volume of 311.66K. It is down -7.10% in the last 24 hours and down -22.16% over the past month. Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

Previous Close:

$1.55

Open:

$1.61

24h Volume:

311.66K

Relative Volume:

0.42

Market Cap:

$64.17M

Revenue:

$19.94M

Net Income/Loss:

$-37.37M

P/E Ratio:

-1.3846

EPS:

-1.04

Net Cash Flow:

$-33.38M

1W Performance:

-7.69%

1M Performance:

-22.16%

6M Performance:

-38.46%

1Y Performance:

-71.26%

1-Day Range:

$1.44

$1.6112

1-Week Range:

$1.44

$1.72

52-Week Range:

$1.38

$8.1939

Werewolf Therapeutics Inc Stock (HOWL) Company Profile

Name

Werewolf Therapeutics Inc

Sector

Healthcare (1233)

Industry

Biotechnology (3)

Phone

617-952-0555

Address

200 TALCOTT AVENUE, WATERTOWN

Employee

Twitter

Next Earnings Date

Latest SEC Filings

HOWL's Discussions on Twitter

Compare HOWL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HOWL Werewolf Therapeutics Inc	1.44	64.17M	19.94M	-37.37M	-33.38M	-1.04
VRTX Vertex Pharmaceuticals Inc	412.11	106.13B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	733.59	80.61B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	649.26	38.82B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	240.55	31.03B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	122.15	29.28B	3.30B	-501.07M	1.03B	-2.1146

Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-03-24	Initiated	JMP Securities	Mkt Outperform
Aug-24-23	Initiated	Wedbush	Outperform
Jun-06-23	Resumed	Jefferies	Buy
Sep-10-21	Initiated	BofA Securities	Buy
May-25-21	Initiated	Evercore ISI	Outperform
May-25-21	Initiated	H.C. Wainwright	Buy
May-25-21	Initiated	Jefferies	Buy
May-25-21	Initiated	SVB Leerink	Outperform

View All

Werewolf Therapeutics Inc Stock (HOWL) Latest News

03:24 AM

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shares Acquired by Geode Capital Management LLC - Defense World

03:24 AM

Jan 09, 2025

Barclays PLC Buys 30,990 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

Jan 09, 2025

Jan 03, 2025

State Street Corp Has $1.01 Million Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

Jan 03, 2025

Dec 31, 2024

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 23.6% in December - MarketBeat

Dec 31, 2024

Dec 18, 2024

Werewolf Therapeutics stock hits 52-week low at $1.58 By Investing.com - Investing.com UK

Dec 18, 2024

Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Drops By 6.1% - Defense World

Dec 18, 2024

Dec 17, 2024

Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Declines By 6.1% - MarketBeat

Dec 17, 2024

Dec 14, 2024

Werewolf Therapeutics' SWOT analysis: oncology stock's potential amid clinical trials - Investing.com Australia

Dec 14, 2024

Nov 23, 2024

HC Wainwright Reaffirms “Buy” Rating for Werewolf Therapeutics (NASDAQ:HOWL) - Defense World

Nov 23, 2024

Nov 20, 2024

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference - The Manila Times

Nov 20, 2024

Nov 19, 2024

Werewolf Therapeutics stock hits 52-week low at $1.62 - Investing.com India

Nov 19, 2024

Werewolf Therapeutics stock hits 52-week low at $1.62 By Investing.com - Investing.com Canada

Nov 19, 2024

Werewolf Therapeutics stock holds buy rating amid investor concerns over cytokine therapies By Investing.com - Investing.com Canada

Nov 19, 2024

HC Wainwright Reaffirms "Buy" Rating for Werewolf Therapeutics (NASDAQ:HOWL) - MarketBeat

Nov 19, 2024

Nov 15, 2024

PFM Health Sciences, LP Increases Stake in Werewolf Therapeutics Inc - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Werewolf Therapeutics (NASDAQ:HOWL) Has Debt But No Earnings; Should You Worry? - Simply Wall St

Nov 14, 2024

Nov 13, 2024

Equities Analysts Set Expectations for HOWL FY2024 Earnings - MarketBeat

Nov 13, 2024

Werewolf Therapeutics' SWOT analysis: oncology biotech's stock potential amid clinical progress - Investing.com Australia

Nov 13, 2024

Nov 11, 2024

What is HC Wainwright's Forecast for HOWL Q1 Earnings? - MarketBeat

Nov 11, 2024

Nov 08, 2024

Werewolf Therapeutics reports promising trial data for cancer drug By Investing.com - Investing.com South Africa

Nov 08, 2024

Nov 07, 2024